Trial Profile
Comparison of once-daily alogliptin/metformin combination tablets and twice-daily anagliptin/metformin combination tablets switching from twice-daily metformin in Japanese type 2 diabetic patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Alogliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Jul 2022 Primary endpoint has been met. (Comparing the two groups change in HbA1c over the 12-week treatment period, with a non-inferiority margin of 0.4%), as per Results published in the Diabetes Therapy
- 06 Jul 2022 Results published in the Diabetes Therapy
- 23 May 2021 Status changed from active, no longer recruiting to completed.